Showing results (141-150 of 159) with videos related to

Sort By:
Pageof 16
Leukemia|January 9, 2004
A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromesM Stadler, U Germing, K-O Kliche, et al.
Leukemia|August 30, 2002
Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factorsM Oosterveld, P Muus, S Suciu, et al.
Bone Marrow Transplantation|March 7, 1998
Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationV Runde, T de Witte, R Arnold, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 6, 2001
Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Düsseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, AustriaS Burdach, B van Kaick, H J Laws, et al.
Leukemia|September 30, 2005
Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)U Germing, B Hildebrandt, M Pfeilstöcker, et al.
Blood|October 6, 2001
Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDST de Witte, S Suciu, G Verhoef, et al.
Leukemia|May 17, 2003
The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921)M Oosterveld, S Suciu, G Verhoef, et al.
Blood|September 10, 1998
Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89W D Ludwig, H Rieder, C R Bartram, et al.
Blood|November 26, 1999
Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedureR Hehlmann, A Hochhaus, H J Kolb, et al.
Leukemia|September 11, 2009
High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCGE Lengfelder, C Haferlach, S Saussele, et al.
Pageof 16